We've got news for you.

Register on Sunday Times at no cost to receive newsletters, read exclusive articles & more.
Register now

Pfizer burnishes fresh image with plans to slash prices in poor ...


Pfizer burnishes fresh image with plans to slash prices in poor countries

Programme will start with 23 medicines in five countries and eventually include the company’s entire drug portfolio

Drew Armstrong

Pfizer plans to sell its entire portfolio of brand-name drugs at cost in as many as 45 lower-income countries, one of the most comprehensive and ambitious drug-access programmes ever announced by a large pharmaceutical manufacturer. 

The initiative will start in five African countries with 23 drugs for cancer, rare illnesses, inflammatory conditions and infectious diseases. It will eventually include all of the New York-based company’s future therapies or vaccines. The drugs will be sold at the cost of manufacturing, Pfizer said, typically a fraction of their price in US or European markets. The company also plans to invest in local health systems to improve diagnostic capabilities, get the drugs approved and make sure doctors know how to administer them.

Throughout the pandemic, the company has sold its Covid-19 vaccine in lower-income countries for about $7 (about R110) a dose, near where it puts the cost, compared with $19.50 (about R305) in the US. For Covid-19 and other illnesses, peer drugmakers have run similar low-cost programmes, particularly for diseases common in the developing world. But for most drug categories, many of the newest, most advanced therapies can take years to reach low-income markets, if they ever do...

This article is reserved for Sunday Times Daily subscribers.
A subscription gives you full digital access to all Sunday Times Daily content.

Sunday Times Daily

Already subscribed? Simply sign in below.

Questions or problems?
Email helpdesk@timeslive.co.za or call 0860 52 52 00.

Previous Article